Leading science, pioneering therapies
CRM Publications

Modeling Parkinson's disease with induced pluripotent stem cells harboring α-synuclein mutations.

TitleModeling Parkinson's disease with induced pluripotent stem cells harboring α-synuclein mutations.
Publication TypeJournal Article
Year of Publication2017
AuthorsDolt KSingh, Hammachi F, Kunath T
JournalBrain Pathol
Volume27
Issue4
Pagination545-551
Date Published2017 Jul
ISSN1750-3639
Abstract

Parkinson's disease (PD) is a common neurodegenerative condition affecting more than 8 million people worldwide. Although, the majority of PD cases are sporadic in nature, there are a growing number of monogenic mutations identified to cause PD in a highly penetrant manner. Many of these familial mutations give rise to a condition that is clinically and neuropathologically similar, if not identical, to sporadic PD. Mutations in genes such as SNCA cause PD in an autosomal dominant manner and patients have motor and non-motor symptoms that are typical for sporadic PD. With the advent of reprogramming technology it is now possible to capture these mutations in induced pluripotent stem cells (iPSCs) to establish models of PD in a dish. There are multiple neuronal subtypes affected in PD including the midbrain dopaminergic (mDA) neurons of the substantia nigra. Robust neuronal differentiation into mDA or other relevant neural cell types are critical to accurately model the disease and ensure the findings are relevant to understanding the disease process. Another challenge for establishing accurate models of PD is being met by the generation of isogenic control iPSC lines with precise correction of mutations using advanced gene editing technology. The contributions of ageing and environmental factors present further challenges to this field, but significant progress is being made in these areas to establish highly relevant and robust models of PD. These human neuronal models, used in conjunction with other model systems, will vastly improve our understanding of the early stages of the PD, which will be key to identifying disease-modifying and preventative treatments.

DOI10.1111/bpa.12526
Alternate JournalBrain Pathol.
PubMed ID28585381
Publication institute
CRM